Fidia Farmaceutici
Italian Fidia won FDA approval for HYMOVIS ONE, a single-injection hyaluronan therapy for knee osteoarthritis launched at AAOS 2026, and runs the established Hyalgan viscosupplementation line, while EU R&D develops HA–recombinant-collagen combination implants for tissue regeneration.
- Country
- Italy
OA viscosupplementation
HYMOVIS ONE FDA approved
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biosynthetic hyaluronic acid | specialty-fine-chem | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.